基于肠道菌群紊乱调节探讨中医传统运动联合能量限制调控超重/肥胖型糖脂代谢机制

注册号:

Registration number:

ChiCTR2400086866 

最近更新日期:

Date of Last Refreshed on:

2026-05-08 09:20:25 

注册时间:

Date of Registration:

2024-07-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于肠道菌群紊乱调节探讨中医传统运动联合能量限制调控超重/肥胖型糖脂代谢机制

Public title:

Based on the regulation of intestinal flora disturbance To explore the mechanism of traditional Chinese medicine exercise combined with energy restriction to regulate overweight/obese type glucose and lipid metabolism

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中医传统运动联合能量限制通过调节肠道菌群介导的肠黏膜屏障修复改善超重/肥胖型糖脂代谢失调机制研究

Scientific title:

Traditional Chinese exercise combined with energy restriction can improve the mechanism of overweight/obese glucose and lipid metabolism disorder by regulating intestinal mucosal barrier repair mediated by intestinal flora

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈建梅 

研究负责人:

郭建红 

Applicant:

Chen Jianmei 

Study leader:

Guo Jianhong 

申请注册联系人电话:

Applicant telephone:

+86 151 0957 2363

研究负责人电话:

Study leader's
telephone:

+86 139 0958 6158

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1394870278@qq.com

研究负责人电子邮件:

Study leader's E-mail:

guojh63@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

宁夏银川市兴庆区胜利南街1160号

研究负责人通讯地址:

宁夏银川市兴庆区胜利南街1160号

Applicant address:

1160 Shengli Street South, Xingqing District, Yinchuan, Ningxia

Study leader's address:

1160 Shengli Street South, Xingqing District, Yinchuan, Ningxia

申请注册联系人邮政编码:

Applicant postcode:

750004

研究负责人邮政编码:

Study leader's postcode:

750004

申请人所在单位:

宁夏医科大学

Applicant's institution:

Ningxia Medical University

研究负责人所在单位:

宁夏医科大学

Affiliation of the Leader:

Ningxia Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-073

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁夏医科大学伦理审查委员会

Name of the ethic committee:

Medical Ethics Committee of NingXia Medical University (NXMU)

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-28 00:00:00

伦理委员会联系人:

曹媛

Contact Name of the ethic committee:

Cao Yuan

伦理委员会联系地址:

宁夏银川市兴庆区胜利南街1160号

Contact Address of the ethic committee:

1160 Shengli Street South, Xingqing District, Yinchuan, Ningxia

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 951 698 0057

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宁夏医科大学

Primary sponsor:

Ningxia Medical University

研究实施负责(组长)单位地址:

宁夏银川市兴庆区胜利南街1160号

Primary sponsor's address:

1160 Shengli Street South, Xingqing District, Yinchuan, Ningxia

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

宁夏回族自治区

市(区县):

银川

Country:

China

Province:

Ningxia Hui Autonomous Region

City:

Yinchuan

单位(医院):

宁夏医科大学

具体地址:

兴庆区胜利南街1160号

Institution
hospital:

Ningxia Medical University

Address:

1160 Shengli Street South, Xingqing District

经费或物资来源:

课题经费 2023年国家自然科学基金项目(82360967)

Source(s) of funding:

Project funds 2023 National Natural Science Foundation of China Project (82360967)

研究疾病:

超重/肥胖  

Target disease:

overweight/Obesit

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

本研究旨在探究中医传统功法联合能量限制对超重/肥胖人群慢性低度炎症状态及长效减重的作用机制,为该干预模式在超重/肥胖预防与治疗中的临床应用提供理论依据。具体目标包括: (1)明确联合干预对超重/肥胖人群肠道微生态的调节作用,包括肠道菌群结构及肠道代谢物的变化。 (2)评估联合干预对代谢健康相关指标的影响,包括肠黏膜屏障功能、慢性低度炎症状态,以及体重、血压、血糖、血脂、电解质和微量元素等指标。 (3)分析肠道菌群、肠道代谢物与代谢健康指标变化之间的相关关系,探讨其在改善慢性低度炎症及促进体重控制中的潜在机制。  

Objectives of Study:

The present study aims to investigate the mechanisms by which traditional Chinese health exercises combined with energy restriction improve chronic low-grade inflammation and promote long-term weight loss in overweight and obese individuals, thereby providing an important theoretical basis for the clinical application of this intervention in the prevention and treatment of overweight and obesity. The specific objectives are as follows: (1)To clarify the regulatory effects of the combined intervention on the gut microbiota and intestinal metabolites in overweight and obese individuals. (2)To evaluate the effects of the combined intervention on metabolic health indicators, including intestinal mucosal barrier function, chronic low-grade inflammatory status, body weight, blood pressure, blood glucose, blood lipids, electrolytes, and trace elements. (3)To analyze the correlations among the changes in these indicators, in order to explore the potential mechanisms underlying the improvement of chronic low-grade inflammation and long-term weight control.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.近 1 月内服用过影响体重的药物或 1 年内接受过减重手术; 2.过去两个月,各种原因导致体重减轻 5Kg 以上的受试者; 3.因药物、内分泌疾病或其他疾病导致体重增加的继发性肥胖患者; 4.合并严重的肝肾功能障碍或其他严重原发性疾病; 5.肥胖合并高血压、高血脂等慢性病者; 6.各类其它慢性病患者,需长期服药,影响试验结果者; 7.胃肠道疾病患者,及试验前 1 个月使用抗生素、益生元等影响肠道菌群的药物者;

Exclusion criteria:

1. Have taken drugs that affect weight within the past 1 month or have undergone weight-loss surgery within 1 year; 2.Subjects who lost more than 5Kg in the past two months due to various causes; 3. Patients with secondary obesity who gain weight due to drugs, endocrine diseases or other diseases; 4. Combined with severe liver and kidney dysfunction or other serious primary diseases; 5. Obese patients with chronic diseases such as hypertension and hyperlipidemia; 6. Patients with various other chronic diseases who need to take medication for a long time and affect the test results; 7. Patients with gastrointestinal diseases, and those who used antibiotics, prebiotics and other drugs affecting intestinal flora 1 month before the test;

研究实施时间:

Study execute time:

From 2024-07-15 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-09-29 00:00:00 To 2024-09-30 00:00:00

干预措施:

Interventions:

组别:

超重/肥胖能量限制组

样本量:

30

Group:

Overweight/obese energy restriction group

Sample size:

干预措施:

低热量摄入干预

干预措施代码:

Intervention:

Low calorie intake intervention

Intervention code:

组别:

超重/肥胖中医传统运动联合能量限制干预组(辟谷组)

样本量:

30

Group:

Overweight/obese in traditional Chinese medicine exercise group combined with energy restriction group (Bigu group)

Sample size:

干预措施:

传统运动联合无能量摄入干预

干预措施代码:

Intervention:

Traditional exercise combined with no energy intake intervention

Intervention code:

组别:

超重/肥胖养生功法结合低热量限制干预组

样本量:

30

Group:

Overweight/obese in traditional Chinese medicine exercise group combined with low energy restriction group

Sample size:

干预措施:

传统运动联合低能量摄入干预

干预措施代码:

Intervention:

Traditional exercise combined with low energy intake intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

宁夏回族自治区 

市(区县):

银川 

Country:

China

Province:

Ningxia Hui Autonomous Region

City:

Yinchuan

单位(医院):

宁夏医科大学 

单位级别:

大学 

Institution
hospital:

Ningxia Medical University

Level of the institution:

University

测量指标:

Outcomes:

指标中文名:

肠道菌群结构及功能变化

指标类型:

主要指标

Outcome:

Changes in gut microbiota structure and function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪便代谢组学变化

指标类型:

主要指标

Outcome:

Fecal metabolomic changes

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠黏膜屏障功能(血清二胺氧化酶和内毒素水平)

指标类型:

次要指标

Outcome:

Intestinal mucosal barrier function (DAO and ET levels)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重、BMI 和体成分指标

指标类型:

次要指标

Outcome:

Body weight, BMI, and body composition indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖、血脂、胰岛素、糖化血红蛋白等生理生化指标

指标类型:

次要指标

Outcome:

Fasting blood glucose , blood lipid profile, insulin, and glycated hemoglobin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

附加指标

Outcome:

Blood pressure

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血液炎症因子

指标类型:

附加指标

Outcome:

Blood inflammatory factor

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清电解质

指标类型:

附加指标

Outcome:

Serum electrolytes

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清微量元素

指标类型:

附加指标

Outcome:

Serum trace elements

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医体质

指标类型:

附加指标

Outcome:

Traditional Chinese Medicine (TCM) constitution

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 40 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

向课题负责人邮箱索取guojh63@163.com

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Ask for guojh63@163.com from the person in charge of the project.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-07-12 16:08:23